124 related articles for article (PubMed ID: 3013400)
1. Phase II trials of alpha-difluoromethylornithine, an inhibitor of polyamine synthesis, in advanced small cell lung cancer and colon cancer.
Abeloff MD; Rosen ST; Luk GD; Baylin SB; Zeltzman M; Sjoerdsma A
Cancer Treat Rep; 1986 Jul; 70(7):843-5. PubMed ID: 3013400
[TBL] [Abstract][Full Text] [Related]
2. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
3. Long-term maintenance therapy of established human small cell variant lung carcinoma implants in athymic mice with a cyclic regimen of difluoromethylornithine.
Luk GD; Abeloff MD; McCann PP; Sjoerdsma A; Baylin SB
Cancer Res; 1986 Apr; 46(4 Pt 1):1849-53. PubMed ID: 3004708
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice.
Luk GD; Abeloff MD; Griffin CA; Baylin SB
Cancer Res; 1983 Sep; 43(9):4239-43. PubMed ID: 6409400
[TBL] [Abstract][Full Text] [Related]
5. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
6. Anchorage dependency effects on difluoromethylornithine cytotoxicity in human lung carcinoma cells.
Luk GD; Baylin SB
Cancer Res; 1986 Apr; 46(4 Pt 1):1844-8. PubMed ID: 3004707
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Abeloff MD; Slavik M; Luk GD; Griffin CA; Hermann J; Blanc O; Sjoerdsma A; Baylin SB
J Clin Oncol; 1984 Feb; 2(2):124-30. PubMed ID: 6422008
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of antitumor and antimetastatic activities of alpha-difluoromethylornithine by interferon inducers.
Sunkara PS; Prakash NJ; Rosenberger AL; Hagan AC; Lachmann PJ; Mayer GD
Cancer Res; 1984 Jul; 44(7):2799-802. PubMed ID: 6426786
[TBL] [Abstract][Full Text] [Related]
10. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
[TBL] [Abstract][Full Text] [Related]
12. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
14. Additive and differential biological activity of alpha-interferon A, difluoromethylornithine, and their combination on established human lung cancer cell lines.
Bepler G; Carney DN; Nau MM; Gazdar AF; Minna JD
Cancer Res; 1986 Jul; 46(7):3413-9. PubMed ID: 3085922
[TBL] [Abstract][Full Text] [Related]
15. Irreversible ototoxicity associated with difluoromethylornithine.
Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
17. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent.
Raul F
Biochem Soc Trans; 2007 Apr; 35(Pt 2):353-5. PubMed ID: 17371277
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of diaziquone in patients with colon cancer.
Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice.
Kingsnorth AN; King WW; Diekema KA; McCann PP; Ross JS; Malt RA
Cancer Res; 1983 Jun; 43(6):2545-9. PubMed ID: 6406047
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
